

## Recent patents in pharmacogenomics Patent # Subject **Assignee** Inventor(s) **Priority Publication** application date date A nucleic acid encoding a human phosphodiesterase (PDE) US 6376225 PE Corp. Beaslev EM 1/5/2001 4/23/2002 that is an alternative splice form of PDE2A; useful as a mode (Norwalk, CT) Di Francesco V, or target for the identification and development of therapeutic Merkulov GV agents, for recombinant expression of PDE, for monitoring Wang X, the effect of modulators, and in pharmacogenomics. Wei M AVIVA WO 200230562 An integrated biochip system that uses active and multi-force Cheng J, 10/10/2000 4/18/2002 chips to carry out several sequential processing tasks such **Biosciences** Wang X, as separation, purification, and isolation; useful for biomed-(San Diego, Wu L. ical applications such as medical diagnosis, genetic testing, CA) Xu J, prognostics, and pharmacogenomics. Yang W An isolated potassium-channel interactor polypeptide useful WO 200226984 Millennium An W. 4/4/2002 10/31/2000 for treating central nervous-system disorders, epilepsy, spino-Pharma-Betty M, cerebellar ataxia, cardiovascular disorders, and in screening Ling H, ceuticals assays, detection assays (chromosomal mapping, tissue (Cambridge, Rhodes K typing, and forensic biology), and predictive medicine (diag-MA) nostic assays, prognostic assays, clinical-trial monitoring, and pharmacogenomics). WO 200224894 A substantially isolated human protease-inhibitor protein Lexicon Donoho G. 9/21/2000 3/28/2002 (HPI), 86 amino acids long, that shares structural similarity Genetics Friddle CJ. with animal protease inhibitors and other animal proteins (The Wood-Hilbun E including serine protease inhibitors, follistatin, and ovomucoid lands, TX) inhibitors; useful for generating antibodies, as reagents in diagnostic assays, and in pharmacogenomics. WO 200225528 A system for use in delivering decision-supported patient TheraDoc.com Baza ME, 9/21/2000 3/28/2002 Boekweg RJ, data to a clinician, comprising a knowledge module, a (Salt Lake patient module, an inference module, and a user module. Eardley DD, City, UT) The system effectively gathers patient data without a lengthy Evans SR, Harty WF examination of the patient and evaluates the data to identify Lu B. Olson JB. Pestotnik SL, Rubin MA, known or unknown medical conditions. Samore MH, Sande MA, Skolnick MH, Stults BM, Tettelbach WH WO 200222826 A library of nucleic acid-protein (NAP) conjugates compris-Xencor Li M, 9/14/2000 3/21/2002 ing a fusion polypeptide with a nucleic-acid modification (Monrovia, Liu H. (NAM) enzyme and a candidate compound, and an express-CA) Melander C ion vector with a fusion of nucleic acids encoding the NAM enzyme and the candidate protein; useful for detecting the presence of a target analyte in a sample, in screens, and in pharmacogenomic studies. WO 200220764 An isolated human transporter peptide whose sequence is PE Corp. Beasley E, 9/11/2001 3/14/2002 selected from a fully defined sequence of 931 amino acids; (Norwalk, Bonazzi V. useful in identifying modulators of transporter peptides, in Chandramouliswaran I, CT) pharmacogenomic analysis, or as a target for diagnosing a Gan W Yan C disease or predisposition to a disease mediated by the peptide. WO 200220832 Warthoe P 1/12/2001 3/14/2002 A method for determining the presence or absence of a **Atonomics** target nucleic acid in a sample by forming a hybridization (Copenhagen, complex of target and probe that is on the surface of a Denmark) piezoelectric biosensor, and measuring a parameter of the biosensor to detect the target; useful in tumor diagnostics, transplantation analyses, genome diagnostics, pharmacogenomics, and gene expression analysis. EP 1158058 A method of nucleic acid (NA) analysis that initiates contact of Centre Dumas S, 5/19/2000 11/28/2001 at least two NA samples having different radiolabels with an Mallet J. National de array of NAs, then detects the hybrids formed; used to detect la Recherche Vujasinovic T Scientifique and quantify a target NA for diagnosis, to monitor gene expression and compare expression patterns between different (France) cell types, and in pharmacogenomics applications.

Source: Derwent Information, Alexandria, VA. The status of each application is slightly different from country to country. For further details, contact Derwent Information, 1725 Duke Street, Suite 250, Alexandria, VA 22314. Tel: 1 (800) DERWENT (info@derwent.com).